In Russia, the development of the first cancer vaccine based on mRNA technology is ongoing. On September 6, 2024, the General Director of the National Medical Research Radiology Center, Andrey Kaprin, announced the completion of the preclinical trial phase and the submission of a proposal to the Russian Ministry of Health to begin the first phase of clinical trials — on volunteers. It was previously reported that the Herzen Oncology Institute, the Blokhin National Cancer Center, and the Gamaleya National Research Center for Epidemiology and Microbiology are involved in the project to create the Russian cancer vaccine. It is known that this is not a universal product, but a personalized one: tumor material is taken from the patient, its characteristics are analyzed, and a so-called "tumor passport" is created, which is used to produce a vaccine for the specific patient. It is expected that oncologists will be responsible for recruiting volunteers for participation in the clinical trials. The duration of the clinical trials has not yet been specified. During the preclinical stage, the method was tested on laboratory animals (mice).